COEPTIS THERAPEUTICS FACES DELISTING THREAT

TL;DR

**COEP got a delisting notice, big trouble for stock liquidity.**

AI Summary

Coeptis Therapeutics Holdings, Inc. (COEP) announced on January 29, 2024, that it received a notice of delisting or failure to satisfy a continued listing rule or standard. This means the company is at risk of being removed from its current stock exchange, which could make its shares harder to trade and potentially reduce their value. This matters to investors because delisting often signals financial instability or a failure to meet exchange requirements, which can lead to a significant drop in stock price and liquidity.

Why It Matters

A delisting notice indicates serious issues with the company's ability to meet exchange requirements, potentially leading to reduced stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A delisting notice is a severe event that can significantly impair a stock's liquidity and value, indicating fundamental problems with the company's compliance or financial health.

Analyst Insight

A smart investor would carefully review the reasons for the delisting notice and consider the potential for further stock price depreciation and reduced liquidity before making any investment decisions. Monitoring subsequent filings for a plan to regain compliance is crucial.

Key Players & Entities

• Coeptis Therapeutics Holdings, Inc. (company) — the registrant facing delisting
• January 29, 2024 (date) — date of earliest event reported regarding the delisting notice
• 001-39669 (other) — Commission File Number for Coeptis Therapeutics Holdings, Inc.

Forward-Looking Statements

• Coeptis Therapeutics Holdings, Inc. stock price will experience significant volatility. (Coeptis Therapeutics Holdings, Inc.) — high confidence, target: 2024-03-01
• The company will likely announce further details regarding its plan to regain listing compliance. (Coeptis Therapeutics Holdings, Inc.) — medium confidence, target: 2024-04-01

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Mark
• $11.50 — e-half of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capita
• $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing on The
• $2.5 million — hings, a minimum stockholders' equity of$2.5 million and a minimum bid price requirement of

Filing Documents

• coeptis_8k.htm (8-K) — 40KB
• 0001683168-24-000615.txt ( ) — 254KB
• coep-20230129.xsd (EX-101.SCH) — 3KB
• coep-20230129_def.xml (EX-101.DEF) — 26KB
• coep-20230129_lab.xml (EX-101.LAB) — 36KB
• coep-20230129_pre.xml (EX-101.PRE) — 25KB
• coeptis_8k_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 29, 2024, Coeptis Therapeutics Holdings, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock, par value $0.0001 per share ("Common Stock"), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Notice"). The Notice has no immediate effect on the continued listing status of the Company's Common Stock on The Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective. The Company is provided a compliance period of 180 calendar days from the date of the Notice, or until July 29, 2024, to regain compliance with the minimum closing bid requirement, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). If at any time before July 29, 2024, the closing bid price of the Company's Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter will be resolved. If the Company does not regain compliance during the compliance period ending July 29, 2024, then Nasdaq may grant the Company a second 180 calendar day period to regain compliance, provided the Company meets the continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement, and notifies Nasdaq of its intent to cure the deficiency. The Company will continue to monitor the closing bid price of its Common Stock and seek to regain comp

01

Item 8.01 Other Events. The Company is including the below update to its risk factors, for the purpose of supplementing and updating its (i) prospectus dated November 29, 2023 (as previously updated, the "Prospectus 1"), which forms a part of the Company's Registration Statement on Form S-1 (Registration No. 333-275558), and (ii) the prospectus dated June 14, 2023 (as previously updated, the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-333-269782). Our failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of our Common Stock. Our common stock is currently listed for trading on The Nasdaq Capital Market. We must satisfy The Nasdaq Capital Market's continued listing requirements, including, among other things, a minimum stockholders' equity of$2.5 million and a minimum bid price requirement of $1.00 per share or risk delisting, which would have a material adverse effect on our business. A delisting of our common stock from The Nasdaq Capital Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. 2 On January 29, 2024, we received notice from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we were not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq as set forth In Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: February 1, 2024 By: /s/ David Mehalick David Mehalick Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR